News | Women's Health | November 16, 2016

Dilon Diagnostics Becomes Exclusive North American Distributor of GE Discovery NM750b

Dilon will be the only distributor of GE’s molecular breast imaging system in North America

GE Healthcare, Dilon Diagnostics, North America distribution agreement, Discovery NM750b molecular breast imaging system

November 16, 2016 — Dilon Diagnostics and GE Healthcare announced the signing of an agreement for Dilon to be the exclusive distributor of GE's Discovery NM750b molecular breast imaging system in North America.  Last year, GE Healthcare and Dilon Diagnostics signed a global distribution agreement in select world markets.

The Discovery NM750b offers clinicians a tool for imaging of a broad range of patients, including those with dense breasts who may be at higher risk for breast cancer. The power of functional imaging to see early changes is a key factor in early detection in breast cancer.

For more information: www.gehealthcare.com, www.dilon.com

 

Related Content

55-year-old woman who underwent screening mammogram and ultrasound 7 days after first COVID-19 vaccination dose. Screening mammogram and US demonstrated unilateral left axillary lymph node with cortical thickness of 5 mm on ultrasound (not shown). BI-RADS category 0 was assigned. Ultrasound from diagnostic work-up performed 7 days later showed no change in lymph node size. BI-RADS 3 was assigned. #COVIDvaccine #COVID19

55-year-old woman who underwent screening mammogram and ultrasound 7 days after first COVID-19 vaccination dose. Screening mammogram and US demonstrated unilateral left axillary lymph node with cortical thickness of 5 mm on ultrasound (not shown). BI-RADS category 0 was assigned. Ultrasound from diagnostic work-up performed 7 days later showed no change in lymph node size. BI-RADS 3 was assigned.

News | Breast Imaging | February 24, 2021
Examples of the imaging performance of XPCI-CT (b,e) compared to conventional specimen radiography (a,d) and benchmarked against histopathology (c,f). he top row focuses on the similarity between the XPCI-CT slice in (b) and the histological slice in (c). Arrow 1 indicates margin involvement, arrow 2 a variation in density in the internal structure of the tumour mass, arrow 3 tumour-induced inflammation. All this is confirmed by the histological slice in (c), and hardly visible in the conventional image in

Examples of the imaging performance of XPCI-CT (b,e) compared to conventional specimen radiography (a,d) and benchmarked against histopathology (c,f). he top row focuses on the similarity between the XPCI-CT slice in (b) and the histological slice in (c). Arrow 1 indicates margin involvement, arrow 2 a variation in density in the internal structure of the tumour mass, arrow 3 tumour-induced inflammation. All this is confirmed by the histological slice in (c), and hardly visible in the conventional image in (a). The bottom row focuses on the detection of small calcifications, a key feature in DCIS. These are undetectable in (d), detected in (e), enhanced in the maximum intensity projection (MIP) image at the bottom of (f), and confirmed by histopathology in the top part of (f). The scale bar [shown in (b) and (e)] is the same for all images apart from (f), which has its own scale. Red arrows in (e) and (f) indicate the microcalcifications. Image courtesy of Professor Alessandro Olivo

News | Breast Imaging | February 22, 2021
February 22, 2021 — A new X-ray imaging scanne
F-18 FES PET images of patients with ER+/PR+/HER2- invasive ductal carcinoma. Left panel: Progressive disease seen at the 8-week time-point in a patient on sequential therapy. Right panel: Stable disease through all 3 time-points, remaining on study therapy for 6.7 months until disease progression on combined vorinostat aromatase inhibitor therapy. Image created by Lanell M Peterson, Research Scientist, University of Washington Medical Oncology, Seattle WA.

F-18 FES PET images of patients with ER+/PR+/HER2- invasive ductal carcinoma. Left panel: Progressive disease seen at the 8-week time-point in a patient on sequential therapy. Right panel: Stable disease through all 3 time-points, remaining on study therapy for 6.7 months until disease progression on combined vorinostat aromatase inhibitor therapy. Image created by Lanell M Peterson, Research Scientist, University of Washington Medical Oncology, Seattle WA.

News | Molecular Imaging | February 22, 2021
February 22, 2021 — Molecular imaging
A comparison of standard mammography imaging (left) in a woman with dense breasts and a breast MRI imaging study (right) showing a clearly defined cancer and is extremely hard to detect on the mammograms.

A comparison of standard mammography imaging (left) in a woman with dense breasts and a breast MRI imaging study (right) showing a clearly defined cancer and is extremely hard to detect on the mammograms. Images from Christiane Kuhl, M.D.

Feature | MRI Breast | February 17, 2021 | By Dave Fornell, Editor
Dense breast tissue can hide cancers i
Screening strategy based on baseline breast density at age 40 may be effective and cost-effective for reducing breast cancer mortality

Getty Images

News | Breast Density | February 10, 2021
February 10, 2021 — A mammography screenin...
Comparison of breast cancer mortality rates (red squares) and distant-stage breast cancer incidence rates from SEER9 (blue dots) and SEER18 (green dots) per 100,000 for white women aged, A, 20–39, B, 40–69, and, C, 70–79 years (3,7,8).

Comparison of breast cancer mortality rates (red squares) and distant-stage breast cancer incidence rates from SEER9 (blue dots) and SEER18 (green dots) per 100,000 for white women aged, A, 20–39, B, 40–69, and, C, 70–79 years (3,7,8). Image courtesy of Radiology 

News | Breast Imaging | February 10, 2021
February 10, 2021 — Breast cancer death rates have stopped declining for women in the U.S.
After acquiring the molecular breast imaging (MBI) assets from GE Healthcare and Dilon Technologies, Inc., SmartBreast Corporation (SmartBreast), a privately held company focused on breast cancer screening and diagnosis, announced today that it has formed a partnership with FoxSemicon Integrated Technologies, Inc. (FITI) to manufacture molecular breast imaging (MBI) systems.
News | Breast Imaging | February 09, 2021
February 9, 2021 — After acquiring the...

Chart courtesy of the American Cancer Society

News | Breast Imaging | February 08, 2021
February 8, 2021 — Cancer ranks as a leading cause of death in every country in the world, and, for the first time,
Volpara Health, a health technology software company whose integrated breast care platform assists in the delivery of personalized patient care, announced the acquisition of CRA Health, LLC, a breast cancer risk assessment company spinoff from Massachusetts General Hospital — a Harvard Medical School teaching hospital.

Getty Images

News | Breast Imaging | February 02, 2021
February 2, 2021 — Volpara Health, a health technology software company whose integrated...